In brief
Amid heightened scrutiny, former chemical industry lobbyist Lynn Dekleva takes on a powerful role at the EPA, igniting concerns over regulatory oversight and public health.
In a striking turn of events, Lynn Dekleva, an influential former lobbyist for the American Chemistry Council, has assumed a critical position at the Environmental Protection Agency (EPA), where she now oversees the approval of new chemicals. Formaldehyde, a well-known carcinogen widely used in various consumer products, has been at the center of regulatory discussions, especially following the EPA's commitment to enhance regulations in 2021.Following the EPA’s decision to address formaldehyde's potential dangers, Dekleva led a tenacious resistance from the chemicals industry during her time at the lobbying group that invests heavily in influencing government policies. This past association raises questions regarding her current capacity to enforce stringent regulations without bias.Before making the leap to the EPA during the first Trump administration, Dekleva dedicated 32 years to Dupont, a notable chemical manufacturer. Her new responsibilities come at a pivotal time, where the American Chemistry Council has prioritized reversing the EPA’s regulatory stance on formaldehyde and has petitioned the agency to reevaluate its risk assessment procedures for chemicals.Recent developments indicate that the Council is advocating for modifications to the EPA’s approval process to expedite safety reviews—a process that now falls under Dekleva's jurisdiction. Compounding these concerns, Nancy Beck, another former lobbyist from the Council, has also joined the EPA to manage existing chemicals.The president of the American Chemistry Council, Chris Jahn, made clear during a Senate hearing post-Trump's inauguration that the group seeks to combat what they label as “unnecessary regulations” on chemicals, asserting that a robust economy relies on the advancement of chemical usage and innovation. This statement raises alarms about the balance between economic interests and public safety amid critical decisions regarding chemical approvals.
